Phototherapy shows some unique advantages in clinical application, such as remote controllability, improved selectivity, and low bio-toxicity, than chemotherapy. In order to improve the safety and therapeutic efficacy, imaging-guided therapy seems particularly important because it integrates visible information to speculate the distribution and metabolism of the probe. Here we prepare biocompatible core-shell nanocomposites for dual-modality imaging-guided photothermal and photodynamic dual-therapy by the in situ growth of porphyrin-metal organic framework (PMOF) on Fe 3 O 4 @C core. Fe 3 O 4 @C core was used as T 2 -weighted magnetic resonance (MR) imaging and photothermal therapy (PTT) agent. The optical properties of porphyrin were well remained in PMOF, and PMOF was therefore selected for photodynamic therapy (PDT) and fluorescence imaging. Fluorescence and MR dual-modality imaging-guided PTT and PDT dual-therapy was confirmed with tumour-bearing mice as model. The high tumour accumulation of Fe 3 O 4 @C@PMOF and controllable light excitation at the tumour site achieved efficient cancer therapy, but low toxicity was observed to the normal tissues. The results demonstrated that Fe 3 O 4 @C@PMOF was a promising dual-imaging guided PTT and PDT dual-therapy platform for tumour diagnosis and treatment with low cytotoxicity and negligible in vivo toxicity.
1
. Chemotherapy is still the popular means for cancer therapy, but drug-resistance and bio-toxicity are its important limitations 2 . As a consequence, various physiotherapy strategies emerge at the right moment. Phototherapy, including photothermal therapy (PTT) and photodynamic therapy (PDT), shows unique advantages, such as remote controllability, improved selectivity, and low bio-toxicity compared with chemotherapy [3] [4] [5] . Probing the position of photoactive agent becomes important for phototherapy, so multifunctional cancer therapy platforms (MCTPs) attract much attention as they integrate imaging and therapy into a single system for imaging-guided therapy to improve the therapeutic efficiency and safety 6, 7 . Various interesting MCTPs have been fabricated with emissive nanostructures (e.g., Au nanorods and nanoshells) and photosensitizers (e.g., chlorine e6 and indocyanine green) for imaging-synergistic-therapy 8, 9 . However, the systems suffered from single-modality imaging, single-therapy, and/ or complex post-modification. If multi-modality imaging is selected, the advantages of each imaging modality are integrated together, such as high sensitivity of fluorescence and the deep penetration and spatial resolution Scientific RepoRts | 7:44153 | DOI: 10.1038/srep44153 of magnetic resonance (MR) imaging [10] [11] [12] . The dual-therapy combination of PTT and PDT could improve the therapeutic effect significantly [13] [14] [15] . One of the challenges to build MCTPs is the selection of safe and biocompatible building blocks with optical and/or magnetic responses. Porphyrin and its derivatives are widely used as photosensitizers and organic ligands for bioimaging and PDT 16 , due to their unique optoelectronic properties 17, 18 . However, their large hydrophobic planar structure makes porphyrin easily aggregated to quench their fluorescence and decrease the capacity of singlet oxygen generation 19 . Porphyrin-metal-organic frameworks (PMOFs) have the rigid structure and well retain the optoelectronic property of porphyrin.
Superparamagnetic iron oxide nanoparticles (SPIONs) are efficient imaging agents because they shorten transverse relaxation with facile synthesis and excellent biocompatibility 20, 21 . The cluster structure of Fe 3 O 4 nanoparticles is effective to enhance MR imaging efficiency than single-domain nanocrystals because it impairs the longitudinal relaxivity 20, 21 . Moreover, the number and magnetic moment of nanoparticles in an assembly are proportional to transverse relaxivity (r 2 ) 20, 21 . Thus, selection of simple Fe 3 O 4 cluster preparation is useful to improve T 2 -MR imaging efficiency 19 . SPIONs are biodegradable 22 and ferumoxsil and ferumoxide, therefore have been approved by Food and Drug Administration as MR contrast agents [23] [24] [25] . Fe 3 O 4 nanoparticles can convert near-infrared (NIR) irradiation to heat to enable localized damage to cancer cells or tissues. Thus, the combination of magnetic property and local photothermal effect make SPIONs interesting as imaging and therapy agents.
Herein, we report the fluorescence-MR dual-modality imaging-guided PTT-PDT dual-therapy system with novel core-shell Fe 3 31 . Fe 3 O 4 @C nanoparticles were dispersed in the DMF suspension of ZrCl 4 in a hydrothermal procedure for 30 min, and then DMF solution of TCPP was added into the mixture. Fe 3 O 4 @C@PMOF was prepared by the in situ self-assembly of PMOF on the surface of Fe 3 O 4 @C to obtain the core-shell nanocomposites. The proposed method was time-saving and efficient compared with the layer-by-layer self-assembly of MOF 32, 33 . Therefore, a simple strategy was developed to prepare the Fe 3 O 4 @C@PMOF composite. Transmission electron microscopy (TEM) images of Fe 3 O 4 @C and Fe 3 O 4 @C@ PMOF revealed their well-defined micro-structure with the average diameter of 80 and 95 nm, respectively ( Fig. 1a and b) Fig. 1a and b, different to the solid Fe 3 O 4 structure of ferumoxsil and ferumoxide [23] [24] [25] . Thus, improved T 2 -MR imaging efficiency is expected because of the altered proton relaxation effect of the nanocluster structure. The composites less than 100 nm pass through the tumor microenvironment easily and remain for a long time before blood clearance 34 . Moreover, the size of Fe 3 O 4 @C@PMOF was suitable for PDT because the diffusion length of singlet oxygen ( 1 O 2 ) was 90− 120 nm in aqueous environment and 20− 220 nm inside cells 28 . Dynamic light scattering analysis indicated that Fe 3 O 4 @C@PMOF had a relatively narrow size distribution and was well dispersed for real application ( Supplementary Fig. S1 ). − 15.7 and − 3.39 mV of zeta potentials were observed for Fe 3 Fig. S3 ). Thermogravimetric analysis (TGA) results revealed that Fe 3 O 4 @C was highly stable in the tested temperature ( Supplementary Fig. S4 ). The gradual weight loss before 200 °C was attributed to the removal of solvents, including acetone and DMF, from both (Fig. 2a) . This feature provided efficient photothermal capacity. When PMOF shell was covered, a strong absorption peak emerged at 416 nm for Soret band (Fig. 2b) and four peaks at 517, 554, 583, and 634 nm were observed for Q band as the typical character of porphyrin (inset of Fig. 2b ) 16 . Thus, Fe 3 O 4 @C@ PMOF was potential for PDT because of its matched NIR absorption 36 . Single emission peak was observed at 668 nm from Fe 3 O 4 @C@PMOF with 553 nm excitation (Fig. 2c) . Strong NIR emission and long Stocks shift led to a high signal/noise ratio for fluorescent image because of the low auto-fluorescence and scattering light from biological tissue 37, 38 . The optical property of Fe 3 O 4 @C@PMOF illustrated its PTT and PDT potential and fluorescence imaging capacity.
T 2 -weighted imaging was tested to validate the MR contrast potential of Fe 3 O 4 @C@PMOF nanocomposites. The relaxation rates vary linearly with increased Fe concentration (Fig. 2d) . The darkening T 2 MR imaging at different Fe concentrations confirmed the T 2 -weighted MR efficiency (Inset of Fig. 2d ). Fe content of Fe 3 O 4 @C@ PMOF was tested by inductively coupled plasma-atomic emission spectroscopy, and the slope in Fig. 2d was the r 2 value, which was 72.6 mM Supplementary Fig. S5 ). The r 2 value was higher than that of commercial magnetic nanoparticles (10 nm, r 2 = 59.91 ± 6 mM −1 s In vitro photothermal and photodynamic properties of Fe 3 O 4 @C@PMOF. PTT efficiency of Fe 3 O 4 @C@PMOF was evaluated by measuring the temperature change under 808 nm NIR laser irradiation (Fig. 3a) . After a 5 min of laser exposure, the solutions containing Fe 3 O 4 @C and Fe 3 O 4 @C@PMOF respectively were rapidly heated to higher than 50 °C because of the high NIR absorptivity of Fe 3 O 4 , while the PBS solution showed less photo-generated heating efficiency ( Supplementary Fig. S6 ). However, when Fe 3 O 4 @C@PMOF solution was exposed to 655 nm laser for 30 min, the temperature gave rise to 29 °C, which was negligible to damage cancer cells (Supplementary Fig. S7 ). Infrared thermal photographs of Fe 3 O 4 @C@PMOF solution before and after 808 nm irradiation illustrated the photothermal capacity directly (Fig. 3b) .
Singlet oxygen ( 1 O 2 ) is the electronic excited state of molecular oxygen and highly reactive in the oxidization damage of biological tissues 4, 28 40 . The reaction was monitored by the decreased ABDA absorption at 379 nm. The absorption spectra of ABDA in Fe 3 O 4 @C@PMOF were recorded at different exposure times (Fig. 3c) , and the variation of absorbance was illustrated in Fig. 3d Fig. S9 ). Thus, their optical properties were well remained in the nanocomposites. Moreover, PTT and PDT were regarded as two independent processes from Fe 3 O 4 @C and PMOF, respectively. illness and activity changes was observed from the mice, which also showed the same weight trend to the mice in control group within 3 weeks (Fig. 4b) .
Cytotoxicity and photoxicity of Fe
In vivo dual-modality imaging of mice with Fe 3 O 4 @C@PMOF as probe and clearance study. To prove the in vivo efficiency of dual-modality imaging, Fe 3 O 4 @C@PMOF nanocomposite was injected Fig. S10 ). The liver region was darkening after being injected for 22 h. The same result was observed in fluorescence imaging simultaneously. The fluorescent spot was also observed in lymph possibly because of the high affinity between porphyrin and lymph node. Thus, the nanocomposites did transfer not only through blood circulation but also participate in the lymph circulation simultaneously. Then, it accumulated in liver. Finally, most of Fe 3 O 4 @C@ PMOF was excreted through excrement within 8 days with the similar metabolic pathway to coproporphyrin 42 . The images in Fig. 5 illustrated the whole metabolism process of Fe 3 O 4 @C@PMOF in nude mice after intravenously injected at different time.
To verify the accumulation of Fe 3 O 4 @C@PMOF in tumor site, MCF-7 tumor-bearing nude mice were selected as model (Fig. 6a) . After being intravenously injected with Fe 3 O 4 @C@PMOF for 22 h, fluorescent signal was localized mainly in the liver region than the other organs. The tumor region was lightened slowly and became the brightest tissue of the mice via enhanced permeability and retention (EPR) effect after 26 h. In vivo T 2 MR image was also recorded simultaneously (Fig. 6c) . The dramatic dimming was observed at tumor area and also demonstrated the high tumor uptake of Fe 3 O 4 @C@PMOF, which was the same as the fluorescence imaging result. To further evaluate the tissue distribution of the nanocomposites, major organs dissected from the mice were harvested and imaged ex vivo at 26 h post injection (Fig. 6b) . The highest fluorescent intensity of cancer tissue indicated tumor-targeted delivery for imaging, PDT and PTT. The intestine was also lightened and indicated the potential metabolic pathway that Fe 3 O 4 @C@PMOF was excreted through excrement. To further study the excretion of the nanocomposites, high level of Fe was detected in feces of mice after injected with Fe 3 O 4 @C@PMOF (Fig. 6d) . Thus, both MR and fluorescent imaging results and ex vivo fluorescence images of the tissues confirmed the efficient tumor location of our nanocomposites.
In vivo photothermal and photodynamic synergetic therapy. Motivated by its high tumor accumulation, Fe 3 O 4 @C@PMOF was used for in vivo imaging-guided tumor treatment. Nude mice with subcutaneous MCF-7 breast cancer xenografts were selected as model. For in vivo monitoring of the photothermal effect generated from Fe 3 O 4 @C@PMOF, the temperature change of the tumor site was recorded with infrared camera under irradiation of 808 nm laser. To study the in vivo synergetic efficiency of PTT and PDT, MCF-7 tumor-bearing mice were randomly divided into five groups. The group injected with saline was regarded as the negative control. All of the other four groups were injected with Fe 3 O 4 @C@PMOF (10 mg kg −1 ). The injected mice without any irradiation were used as the positive control. After the injection for 26 h, the irradiation was carried out. In PTT group, the mice after injection with Fe 3 O 4 @C@PMOF were irradiated with 808 nm laser for 10 min; the mice in PDT group were subjected to the irradiation of 655 nm laser for 10 min. In the PTT-PDT co-therapy group, the mice were firstly irradiated with 808 nm laser for 10 min, followed by the irradiation of 655 nm laser for 10 min. Upon 808 nm laser irradiation, the temperature of the tumor site in the PTT and PTT-PDT co-therapy groups rapidly increased to higher than 50 °C, which is high enough to ablate the cancer cells. For the negative control groups, the tumor tissues didn't show any significant temperature elevation (Fig. 7a) . The injection and irradiation were repeated every two days within 8 days. Tumor sizes and body weights of the mice were monitored every two day after different treatments ( Fig. 7b and Supplementary Fig. S11 ). The size of tumors was normalized to their initial size. Experimental results indicated that the tumor sizes of mice in both negative and positive control groups became larger and larger. In contrast, the tumor growth of the mice after single PTT or PDT inhibited remarkably within 8 days. The PTT-PDT co-therapy group exhibited the highest therapeutic efficacy compared with that of the single PTT or PDT groups. (Fig. 7b and d) .
Apoptotic and necrotic tumor cells were tested to validate the photo-therapy efficiency (Fig. 8b) . Intensive necrosis area was markedly stained by eosin in the dominated tumor section of PTT-PDT treatment group. The results clearly demonstrated that the synergetic therapeutic efficacy of PTT and PDT was superior to any single therapy. The mice after PTT and PDT treatment behaved normally and the weight didn't decrease remarkably ( Supplementary Fig. S11 ). No pathological changes was noticed for mice after 8 days after PTT and/or PDT, as revealed by hematoxylin and eosin (H&E)-stained major organ slices of the mice because of the excellent biocompatibility of the nanocomposites and the remote controllability, improved selectivity, and safety of phototherapy.
Discussion
In summary, we developed Fe 3 O 4 @C@PMOF for fluorescence-magnetic resonance dual-modality imaging-guided photothermal and photodynamic cancer dual-therapy by in situ growth PMOF shell on Fe 3 O 4 @C core for the first time. The Fe 3 O 4 @C@PMOF nanocomposites featured with some unique advantages over common therapy agents, such as high biocompatibility and stability, and simple self-assembly process to form the MOF shell with the abundant carboxylic groups in the periphery of Fe 3 O 4 @C to interact with Zr 4+ ions. Effective photothermal and photodynamic therapy of tumors was achieved by passive tumor targeting and excellent photophysical properties of the nanocomposites. Besides, the improved safety and low bio-toxicity of phototherapy, different to chemotherapy, had no damage to normal tissues because of the controllable and local irradiation of the laser. Both irradiation and emission of photo-therapy and fluorescence imaging were around infrared or NIR region, so high penetration depth achieved the efficient photo-therapy and imaging. The mice were housed one per cage in a specific pathogen-free environment and had free access to standard solid pellet food (HFK, Beijing, China) and water. We confirmed that all experimental protocols were approved by the Institutional Animal Care Committee of Nankai University and all methods were carried out in accordance with the relevant guidelines and regulations from the Institutional Animal Care Committee of Nankai University. 31 . Briefly, 0.08 g of ferrocene was dissolved in 32 mL acetone. 0.4 mL of 30% hydrogen peroxide was added and the mixture solution was transferred to a 50 mL Teflon-lined stainless autoclave. The mixture was then kept at 210 °C for 24 h. After the autoclave was cooled to room temperature, the products were collected by a magnet after ultrasonication for 20 min. Black solid was washed with acetone and ethanol three times and dried in vacuum at 40 °C for 24 h to obtain Fe 3 O 4 @C nanospheres. In vivo MR imaging. In vivo MR imaging was performed on the mice or MCF-7 tumor-bearing mice anesthetized with 4% chloral hydrate (6 mL kg −1 ). After intravenous injection of Fe 3 O 4 @C@PMOF solution (20 mg kg −1 ) into the mice, the MR images were recorded by positioning the mice on the animal plate of imaging system. The MR imaging was recorded on a 1.2 T MR imaging system, Huantong, Shanghai, China. Images were obtained using a small animal coil, before and at subsequent intervals following injection with the imaging sequence: TR/TE = 300/32.6 ms; FOV = 50 mm × 80 mm; matrix = 512 × 256; slice thickness = 0.4 mm without gap; 128 coronal or axial slices. To study the contents of nanocomposites in excretion of mice, mice after intravenous injection with Fe 3 O 4 @C@PMOF were housed in metabolic cages to collect their urine and feces. The collected urine and feces were digested by chloroazotic acid and measured by ICP-AES.
Synthesis of Fe

Preparation of Fe
In vivo fluorescence imaging. In vivo fluorescence images of nude mice and tumor-bearing mice were recorded after anesthetized with 4% chloral hydrate (6 mL kg ) for 10 min, respectively. The weights and tumor sizes of the mice were monitored simultaneously. The tumor volumes were calculated as (width 2 × length)/2 based on the previous report 28 . The main organs of mice were collected after treatment for 8 days. Hematoxylin and eosin (H&E) stained images were used to investigate the biotoxicity. The body weights of the mice were assessed with a counter balance within 8 days.
